PAM Stock Recent News

The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like PCB, GIII, ROCK, PFE and PAM hold promise.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to advance preclinical portfolio Indivior selected GABAB PAM drug candidate and started IND enabling studies for development in substance use disorders Addex selected independent GABAB PAM drug candidate for development in chronic cough Repositioned our phase 2 mGlu5 NAM asset, dipraglurant in brain injury recovery Regained rights to our phase 2 mGlu2 PAM asset, ADX71149 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 25, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its full-year 2024 financial results for the period ended December 31, 2024 and provided a corporate update.

Utility stocks have long been a favorite for investors who are looking for stability and consistent returns in the current market.

Pampa (PAM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

DPMLF, PAM, MTAL, HRTX and BALY have been added to the Zacks Rank #1 (Strong Buy) List on April 22, 2025.

AES, PAM and DPMLF made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 22, 2025.

HOUSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Wound care patients across the PAM Health network of hospitals and outpatient clinics will now have access to an innovative new treatment to accelerate chronic wound healing. A multi-year exclusive agreement between PAM Health and Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial-stage medical device company at the forefront of biodynamic therapies, means Nuo's Aurix System will serve as the sole platelet-rich plasma (PRP) wound care therapy across all of PAM Health's long-term acute care hospitals, inpatient rehabilitation hospitals, and outpatient and wound care clinics.

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 17, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that following the previously announced termination of development of ADX71149 (JNJ-40411813) in epilepsy, its partner Janssen Pharmaceuticals, Inc. (now known as J&J Innovative Medicine) has return all development and commercialization rights to ADX71149 (JNJ-40411813) and the partnership between the two companies has been terminated.

BUENOS AIRES, AR / ACCESS Newswire / April 16, 2025 / Pampa Energía S.A. (NYSE: PAM)(Buenos Aires Stock Exchange:PAMP) (‘Pampa' or the ‘Company'), one of the leading energy companies in Argentina, with participation in the oil and gas and electricity value chain, announces that on April 16, 2025 it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the ‘2024 Annual Report') before the U.S. Securities and Exchange Commission (the ‘SEC').